Sibel Yurt

Sibel Yurt

Auto-generated profile, based on publicly available information

Sibel Yurt

Basaksehir Cam and Sakura City Hospital, Department of Pulmonology, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2014 in Multidisciplinary Respiratory Medicine
Verified
Journal Article
Open access
PDF file
SYSibel Yurt
Sibel Yurt
CKCanan Kucukgergin
Canan Kucukgergin
BYBurcu Arpinar Yigitbas
Burcu Arpinar Yigitbas
ŞSŞule Seçkin
Şule Seçkin
HTHüseyin Cem Tigin
Hüseyin Cem Tigin
AKAyşe Filiz Koşar
Ayşe Filiz Koşar
To evaluate and compare the diagnostic efficiency of serum (s) and pleural (p) levels of adenosine deaminase (ADA)-1, ADA-2, total ADA, and interferon-gamma (IFN-γ) for the differential diagnosis of pleural tuberculosis (TB).

1 January 2013 in Clinical Biochemistry
Verified
Journal Article
Closed access
SYS. Yurt
S. Yurt
HEH. Erman
H. Erman
GKG.G. Korkmaz
G.G. Korkmaz
AKA.F. Kosar
A.F. Kosar
PUP. Uysal
P. Uysal
HUHafize Uzun
Hafize Uzun

30 August 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Closed access
HÇHalit Çinarka
Halit Çinarka
GGGülşah Günlüoğlu
Gülşah Günlüoğlu
MÇMustafa Çörtük
Mustafa Çörtük
SYSibel Yurt
Sibel Yurt
MKMurat Kiyik
Murat Kiyik
EÇErdoğan Çetinkaya
Erdoğan Çetinkaya
Background/aim: SARS-CoV-2, a ribonucleic acid coronavirus, rapidly spread worldwide within a short timeframe. Although different antiviral, antiinflammatory, and immunomodulatory drugs are used, current evidence is insufficient as to which drug is more efficient. Our study compared favipiravir and lopinavir/ritonavir (LPV/RTV) therapies in inpatient care for coronavirus disease 2019 (COVID-19) pneumonia. Materials and methods: Demographic data, test results, treatments, and latest status of patients receiving inpatient COVID-19 pneumonia therapy were recorded. The initial favipiravir and LPV/RTV receiving groups were compared regarding the need for intensive care units (ICU) and mortality. Logistic regression analysis was performed by including variables showing significant differences as a result of paired comparisons into the model. Results: Of the 204 patients with COVID-19 pneumonia, 59 (28.9%), 131 (64.2%), and 14 were administered LPV/RTV, favipiravir, and favipiravir with LPV/RTV, respectively. No difference was found in age, sex, presence of comorbidity, and tocilizumab, systemic corticosteroid, and plasma therapy use between patients administered with these three different treatment regimens. The mean mortality age of the patients was 71 +/- 14.3 years, which was substantially greater than that of the survivors (54.2 +/- 15.5 years). Compared with patients administered with LPV/RTV, ICU admission and mortality rates were lower in patients administered with favipiravir. CK-MB, AST, CRP, LDH, and creatinine levels were higher, whereas lymphocyte counts were lower in patients who died. Age, AST, CRP, LDH, and neutrophil counts were higher in patients needing ICU, and eosinophil and lymphocyte counts were significantly lower. Logistic regression analysis showed that favipiravir use independently decreased mortality (p = 0.006). Conclusion: The use of favipiravir was more effective than LPV/RTV in reducing mortality in hospitalized patients with COVID-19.

29 December 2015 in Tuberk Toraks
Verified
Journal Article
Closed access
FKFiliz Koşar
Filiz Koşar
SYSibel Yurt
Sibel Yurt
BYBurcu Arpi̇nar Yi̇ği̇tbaş
Burcu Arpi̇nar Yi̇ği̇tbaş
BŞBarış ŞEKER
Barış ŞEKER
HÖHatice Kutbay Özçeli̇k
Hatice Kutbay Özçeli̇k
HUHafize Uzun
Hafize Uzun
The aim of the present study was to evaluate and compare the diagnostic accuracy of pleura levels of adenosine deaminase (ADA) and neopterin for the differential diagnosis of pleural tuberculosis (TP). The study included 50 patients with TB, 27 patients with malignancies, and 24 patients with pleural effusion of non-tuberculous and non-malignant origin as controls. ADA and neopterin levels in pleural fluid were measured by spectrofotometric and ELISA method, respectively. Pleural neopterin levels were significantly higher in patients with pleural TB than patients with malignancy (p< 0.001). Pleural ADA levels were significantly higher in patients with pleural TB than patients with malignancy (p< 0.001) and patients with benign non-tuberculosis effusions (p< 0.001). The mean levels of ADA and neopterin in pleural effusion were evaluated according to their underlying diseases for the diagnostic accuracy. As for pleural TB receiving operating characteristic curves identified the following results; The best cut-off value for pleural neopterin was 4.7 U/L and yielded a sensitivity and specificity of 86% and 72.55%, respectively. Taking a cut-off value of 42 U/L for pleural ADA, the sensitivity and the specificity were found to be 88% and 68.63%, respectively. In the diagnosis of pleural TB pleural neopterin level has a comparable sensitivity to pleural ADA activity. Both markers may find a place as a routine investigation in the coming days for early detection of TB. However, these tests should not be considered an alternative to biopsy and culture.

9 February 2024 in Medicine
Verified
Journal Article
Open access
KKKemal Karapınar
Kemal Karapınar
SYSibel Yurt
Sibel Yurt
MTMehmet Toptaş
Mehmet Toptaş
ABAyse Bahadir
Ayse Bahadir
VEVolkan Erdoğu
Volkan Erdoğu
SOSeda Tural Onur
Seda Tural Onur
Interstitial lung disease (ILD) independently heightens the risk of lung cancer (LC), often necessitating chemoradiotherapy (CRT) due to advanced disease stages. However, CRT may compromise survival through complications such as ILD exacerbation or radiation pneumonitis. The aim of this study was to determine the optimal surgical or nonsurgical treatment approaches for patients with concurrent ILD and LC. Over a 10-year period, a retrospective evaluation was conducted on 647 patients with confirmed diagnoses of LC and ILD from a total of 4541 patients examined in the polyclinic. This assessment included a comprehensive review of demographic, treatment, and survival records. Study groups included those treated for both ILD and LC with surgical treatment (ST), chemotherapy (CT), radiotherapy (RT), or CRT. A control group comprised ILD-only cases. In the whole sample of 647 patients with complete data, the length of stay in hospital and respiratory intensive care unit was significantly shorter in the ST group and longer in the CT group. Significant differences in discharge status (P < .001) were observed, with higher recovery rates in the ST and RT groups. The CT group showed an increased rate of transfer to other centers, in-hospital mortality was determined to be higher in the CRT group, and the control group exhibited no change in discharge. No statistically significant difference was determined between the groups with respect to the 24- and 48-month survival rates (P = .100). Although no disparity was found in 2- and 4-year survival rates, there were seen to be advantages in survival and quality of life with the addition of radiotherapy to regions aligning with surgical margins for LC patients with ILD, evaluated as radiological N0, undergoing wedge resection. This underscores the need for personalized treatment strategies to balance effective cancer control and to minimize ILD-related complications.

1 December 2018 in Journal of Infectiology
Verified
Journal Article
Open access
SYSibel Yurt
Sibel Yurt
GKGamze Kirkil
Gamze Kirkil
Pleural tuberculosis is the most common cause of pleural effusion (PE) worldwide